Kronos Bio (KRON) Stock Price, News & Analysis

Company Overview

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision therapeutics for patients with cancer. Founded in 2018 and based in Cambridge, Massachusetts, Kronos Bio applies its proprietary functional genomics platform to identify and validate vulnerabilities in transcriptional and epigenetic regulation that drive tumor growth. By integrating advanced screening technologies, the company aims to accelerate target identification and optimize small-molecule drug candidates with high potency and selectivity.

The company’s lead programs focus on selective inhibitors of cyclin-dependent kinase 9 (CDK9), a critical regulator of gene expression in cancer cells, and novel modulators of transcriptional machinery that have demonstrated the potential to overcome resistance mechanisms associated with existing therapies. Kronos Bio’s pipeline includes clinical-stage candidates that have entered early-phase studies in the United States, with plans to expand into European centers to evaluate safety, pharmacodynamics and preliminary efficacy in multiple hematological and solid tumor indications.

Kronos Bio’s research and development efforts are supported by a team of experienced industry leaders and scientific founders with deep expertise in oncology drug discovery and translational medicine. The leadership team is committed to advancing a disciplined clinical strategy, leveraging biomarker-driven patient selection to maximize therapeutic benefit and inform subsequent trial design. Strategic collaborations with academic institutions and contract research organizations enable Kronos Bio to maintain flexibility in resource allocation while driving programs toward key value-inflection milestones.

With a focus on precision oncology and a growing clinical portfolio, Kronos Bio is positioned to address high unmet medical needs in cancer treatment. The company’s approach reflects an emphasis on rigorous target validation, translational research and biomarker development, all aimed at delivering innovative therapies that can improve long-term outcomes for patients facing aggressive malignancies.

Key Stats

• Today's Range: $0.87 to $0.88
• 50-Day Range: $0.67 to $0.89
• 52-Week Range: $0.65 to $1.51
• Volume: 54,089 shs
• Average Volume: 366,193 shs
• Market Capitalization: $53.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.63
• Consensus Rating: Hold

KRON Stock Analysis - Frequently Asked Questions

How have KRON shares performed this year?

Kronos Bio's stock was trading at $0.95 at the beginning of 2025. Since then, KRON stock has decreased by 7.4% and is now trading at $0.88.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) announced its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The firm had revenue of $2.27 million for the quarter, compared to the consensus estimate of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kronos Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRON
• CIK: 1741830
• Web: kronosbio.com
• Phone: 650-781-5200
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kronos Bio: $1.63
• High Price Target: $2.25
• Low Price Target: $1.00
• Potential Upside/Downside: +84.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.08 million
• Net Margins: -701.53%
• Pretax Margin: -701.53%
• Return on Equity: -64.22%
• Return on Assets: -47.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.93
• Quick Ratio: 12.93

Sales & Book Value

• Annual Sales: $9.85 million
• Price / Sales: 5.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.45 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 61,050,000
• Free Float: 46,155,000
• Market Cap: $53.72 million
• Optionable: Optionable
• Beta: 1.64